Boulder, CO – Sept. 8, 2021 – LightDeck Diagnostics today announced additions to its executive leadership team, naming Russ Peloquin as Chief Commercial Officer and Frank Gill as Chief Product Officer. The two will be joining newly-appointed CEO Nick Traggis and CIO Chris Myatt in leading the company’s efforts to commercialize its planar waveguide-powered platform and advance point-of-care diagnostics.

As Chief Commercial Officer, Peloquin brings over 20 years of experience in commercial leadership and business development from some of the top publicly traded diagnostics companies. He recently served as Vice President of Global Commercial Operations at SQI Diagnostics and has also led teams at Quest Diagnostics, Luminex Diagnostics, and Nordiag AB. As LightDeck prepares to scale, Peloquin’s leadership experience at top commercial operations of all sizes will be invaluable in navigating the company’s accelerated growth.

“I’ve had the honor of helping build clinical diagnostics organizations from various life cycle stages. Right now, LightDeck is in a stage of rapid growth, with an ambitious goal to ramp up production from fifty thousand tests per month to one million per month by this time next year,” remarked Russ Peloquin, Chief Commercial Officer of LightDeck. “With $35 million in recent funding and an experienced leadership team, I’m confident we’ll realize this goal and make a massive impact on the market.”

Gill has been a member of the LightDeck team since August 2020, serving as Vice President of Manufacturing. His elevation to Chief Product Officer will support the company’s expansion of its product line and scale-up of production to meet customer demand. Within the past year, Gill has overseen the final manufacturing process development of LightDeck’s suite of healthcare, veterinary, and water diagnostics products; including LightDeck’s upcoming COVID-19 Ultra-Rapid Antigen and Total Antibody tests. Before joining LightDeck in August 2020, Gill served as Vice President of Operations at iCarbonX, OPKO Diagnostics, and Rheonix.

“It’s one thing to design incredible technology, and it’s another to manufacture it at scale,” said CEO Nick Traggis. “Frank has been a vital part of turning our technology into a reproducible and scalable product platform and was a key player in securing $35 million in funding from BARDA just a few months ago. His core knowledge of our technology and capabilities, along with his expertise in operations, will be a massive value-add as we navigate the expansion of our production facilities with this funding.”

Beyond human in-vitro diagnostics, veterinary and water testing applications of LightDeck’s analyzers are already commercially available. LightDeck has a robust product pipeline behind its upcoming 5-minute COVID offerings, including tests for inflammation markers and cardiac triage.

To learn more about LightDeck Diagnostics’ team and offerings, visit: www.LightDeckDx.com About LightDeck Diagnostics

LightDeck Diagnostics believes in a new approach to healthcare, where quick and accurate diagnostic tests will be run wherever and whenever they are needed, without compromise. The company’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. The LightDeck platform is achieving success in veterinary diagnostics and environmental testing. LightDeck is also introducing a portfolio of in vitro diagnostic panels, the first is a 5 minute on-the-spot test for COVID-19.

###